Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2025)

Indivior Pharmaceuticals has reported Long-Term Deferred Tax over the past 5 years, most recently at $323.0 million for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $323.0 million for Q4 2025, up 16.61% from a year ago — trailing twelve months through Dec 2025 was $323.0 million (up 16.61% YoY), and the annual figure for FY2025 was $323.0 million, up 16.61%.
  • Long-Term Deferred Tax for Q4 2025 was $323.0 million at Indivior Pharmaceuticals, up from $285.0 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for INDV hit a ceiling of $323.0 million in Q4 2025 and a floor of $105.0 million in Q4 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $278.0 million (2024), compared with a mean of $255.5 million.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 108.57% in 2022 and later decreased 3.15% in 2024.
  • Indivior Pharmaceuticals' Long-Term Deferred Tax stood at $105.0 million in 2021, then skyrocketed by 108.57% to $219.0 million in 2022, then surged by 30.59% to $286.0 million in 2023, then dropped by 3.15% to $277.0 million in 2024, then grew by 16.61% to $323.0 million in 2025.
  • The last three reported values for Long-Term Deferred Tax were $323.0 million (Q4 2025), $285.0 million (Q3 2025), and $270.0 million (Q2 2025) per Business Quant data.